Amgen Announces the European Medicines Agency Acceptance of Kyprolis & #174; (carfilzomib) Marketing Authorization Application for the Treatement of Relapsed Multiple Myeloma

Kyprolis (carfilzomib) is currently under accelerated review by the European Medicines Agency (EMA) for treatment of patients with relapsed multiple myeloma who have received at least one prior therapy! "Achieving deep and durable responses for patients with relapsed multiple myeloma is critical towards extending the time they live without their disease progressing," said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. "We look forward to working with European regulators to potentially make this important medication available."
Source: International Myeloma Foundation - Category: Hematology Source Type: news